Skip to main content

Table 6 Metabolic parameters from WT and MKR mice at baseline, and after 2 weeks of treatment with CL-316,243 tor vehicle

From: The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice

  WT vehicle WT CL-316,243 MKR vehicle MKR CL-316,243
  Baseline 2 weeks Baseline 2 weeks Baseline 2 weeks Baseline 2 weeks
Body weight (g) 27.95 (0.93) 28.47 (1.13) 28.03 (0.48) 27.15 (0.55) 23.97 (1.07)a 24.19 (0.63) 22.15 (0.59) 22.16 (0.23)
Blood glucose (mg/dL) 146.43 (2.89) 157.29 (6.71) 152.75 (5.55) 184.88 (10.28) 387.60 (52.33)a 380.80 (24.37) 335.40 (36.10) 226.20 (16.23)b
Body fat (%) 14.02 (1.26) 12.83 (1.36) 12.58 (0.92) 6.41 (0.51)c 11.28 (0.71) 11.00 (1.07) 12.45 (0.77) 4.46 (0.40)b
Serum TG (mmol/L)   2.29 (0.06)   1.62 (0.03)d   4.90 (0.10)e   3.77 (0.04)f
Plasma insulin (ng/ml)   1.50 (0.97)   0.82 (0.51)   8.58 (3.85)e   0.80 (0.28)f
  1. Metabolic parameters from wild type (WT) and MKR mice at baseline and after 2 weeks of treatment with CL-316,243. Data in table are means of each group and SEM in parenthesis. One Way ANOVA analysis and Tukey-Kramer post-hoc significance test was performed, assuming a significance level of 5%. The following differences in the group means were found: aMKR Vehicle Baseline vs WT Vehicle Baseline; bMKR CL-316,243 2 weeks vs MKR CL-316,243 Baseline; cWT CL-316,243 2 weeks vs WT CL-316,243 Baseline; dWT CL-316,243 2 weeks vs WT Vehicle 2 weeks; eMKR Vehicle 2 weeks vs WT Vehicle 2 weeks; fMKR CL-316,243 2 weeks vs MKR Vehicle 2 weeks.